NSN Co. Ltd (031860) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NSN Co. Ltd (031860) has a cash flow conversion efficiency ratio of -0.143x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.89 Billion ≈ $-1.96 Million USD) by net assets (₩20.26 Billion ≈ $13.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NSN Co. Ltd (031860) total market value for the company's overall valuation and market capitalisation.
NSN Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how NSN Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
NSN Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NSN Co. Ltd ranked by their cash flow conversion efficiency. Explore NSN Co. Ltd earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Park Ha Biological Technology Co., Ltd.
NASDAQ:BYAH
|
N/A |
|
CANADIAN NORTH RESOURCES
F:EO0
|
0.006x |
|
Swissnet AG
F:81D
|
N/A |
|
PZ Cormay SA
WAR:CRM
|
-0.090x |
|
HEBEI CONSTR.GRP CORP YC1
F:H9D
|
N/A |
|
Principal Technologies Inc
V:PTEC
|
4.320x |
|
SeaStar Medical Holding Corporation
NASDAQ:ICU
|
-0.697x |
|
COINSILIUM GROUP LTD
F:5CT
|
N/A |
Annual Cash Flow Conversion Efficiency for NSN Co. Ltd (2014–2025)
The table below shows the annual cash flow conversion efficiency of NSN Co. Ltd from 2014 to 2025. View latest NSN Co. Ltd stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩20.26 Billion ≈ $13.73 Million |
₩-8.86 Billion ≈ $-6.01 Million |
-0.437x | -274.65% |
| 2024-12-31 | ₩48.12 Billion ≈ $32.61 Million |
₩-5.62 Billion ≈ $-3.81 Million |
-0.117x | +12.82% |
| 2023-12-31 | ₩59.75 Billion ≈ $40.49 Million |
₩-8.00 Billion ≈ $-5.42 Million |
-0.134x | +29.67% |
| 2022-12-31 | ₩59.58 Billion ≈ $40.38 Million |
₩-11.35 Billion ≈ $-7.69 Million |
-0.190x | +40.54% |
| 2021-12-31 | ₩38.49 Billion ≈ $26.08 Million |
₩-12.33 Billion ≈ $-8.35 Million |
-0.320x | -266.26% |
| 2020-12-31 | ₩51.00 Billion ≈ $34.56 Million |
₩-4.46 Billion ≈ $-3.02 Million |
-0.087x | +54.68% |
| 2019-12-31 | ₩22.70 Billion ≈ $15.38 Million |
₩-4.38 Billion ≈ $-2.97 Million |
-0.193x | +32.29% |
| 2018-12-31 | ₩18.37 Billion ≈ $12.45 Million |
₩-5.23 Billion ≈ $-3.55 Million |
-0.285x | +29.34% |
| 2017-12-31 | ₩20.42 Billion ≈ $13.84 Million |
₩-8.24 Billion ≈ $-5.58 Million |
-0.403x | -46.84% |
| 2016-12-31 | ₩22.41 Billion ≈ $15.18 Million |
₩-6.15 Billion ≈ $-4.17 Million |
-0.275x | +1.90% |
| 2015-12-31 | ₩23.86 Billion ≈ $16.17 Million |
₩-6.68 Billion ≈ $-4.53 Million |
-0.280x | -229.13% |
| 2014-12-31 | ₩29.52 Billion ≈ $20.00 Million |
₩-2.51 Billion ≈ $-1.70 Million |
-0.085x | -- |
About NSN Co. Ltd
DHX Company Co., Ltd. engages in biomedical and distribution businesses in South Korea. The company offers Microbiome to treat intractable skin diseases; REJURUB; and AI digital brain diagnostic device. It also purchases and distributes IT components, including graphics cards, DRAM, CPUs, high-capacity storage, and multi-purpose displays; import and distribution of cosmetics; f and b distribution… Read more